| |
Thursday, December 7, 2023 | 2pm ET / 11am PT In this webinar, explore proven strategies, technology insights, and practical approaches to drive innovation, ensure data reproducibility, and unlock the potential of the Lab of the Future. Register now.
|
|
Today’s Big NewsNov 30, 2023 |
|
Decemeber 5, 2023 | The Edison Ballroom, NYC A celebration of the 50 key players, changemakers and innovators across biotech, pharma and healthcare. The Fierce 50 is a groundbreaking project to identify, elevate and celebrate the individuals and companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. Register Now!
|
|
| By Angus Liu The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere. |
|
|
|
By Annalee Armstrong By the time GSK sealed the deal on Bellus Health in April, the U.K. pharma knew exactly what not to do with the phase 3 chronic cough program. The company had watched Merck & Co. struggle with a rival med called gefapixant, taking notes. |
By Conor Hale Johnson & Johnson MedTech has spent $400 million upfront to purchase Laminar, the designer of a device under development for closing off the heart’s left atrial appendage, where blood clots can form to increase the risk of stroke in people with afib. |
By Zoey Becker The company's Groton, Connecticut, research site is the latest to fall victim to job cuts as part of Pfizer's massive $3.5 billion cost-cutting mission, following layoffs across the U.S. and the U.K. |
By Conor Hale CrossBay’s approach does away with the metal forceps typically needed to reach the inner uterus and has collected clearances in endometrial biopsies and IVF procedures. |
By Nick Paul Taylor Endo is taking its Peyronie's disease campaign from the vegetable aisle to the pool hall. Having initially relied on wonky veg to discuss the men’s health condition, the drugmaker has now brought four people with Peyronie's together to shoot some pool and chat about their experiences. |
By Max Bayer Phenomic AI went from radio silence to two deals in two days, this time signing an antibody-focused pact with Astellas. ShapeTX has also been busy, expanding an existing collaboration with Roche to tack on another target. |
By Andrea Park Several months after earning FDA clearance, a 3D-printed bone graft product is gaining steam, having now been used in a handful of surgical procedures. |
By Kevin Dunleavy Seven weeks after a federal judge dismissed a Novo Nordisk’s lawsuit, which accused a Florida pharmacy of selling unauthorized knockoffs of its GLP-1 Wegovy, Ozempic and Rybelsus, Novo has sued the same company. Brooksville Pharmaceuticals is the target of a refiled Novo lawsuit, this one claiming there are impurities in the company’s compounded versions of the popular weight loss treatments. Also facing the same complaint is another Florida company, Wells Pharmacy. |
By Nick Paul Taylor AbbVie has its eyes on accelerated approval of its c-Met antibody-drug conjugate (ADC). The candidate achieved a 35% response rate in a subset of lung cancer patients, spurring plans to talk to regulators, but unfavorable comparisons to an earlier data drop partly took the shine off the update. |
Fierce podcastsDon’t miss an episode |
| This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
|
Thursday, December 7, 2023 | 2pm ET / 11am PT Unlock the secrets to affordable autologous cell therapy manufacturing! Join our webinar to learn about cutting-edge solutions. Discover cost-effective closed-system designs for commercial scale production, bridging the gap between innovation and accessibility. Don't miss out on valuable insights into minimizing expenses in labor, equipment, materials, and facility footprint. Register now.
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
